PRAGUE, Czechia—In patients with an ejection fraction > 40% recovering from a worsening heart failure (HF) event, sacubitril/valsartan (Entresto; Novartis) led to greater reductions in NT-proBNP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results